Edward F Nash
Overview
Explore the profile of Edward F Nash including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
660
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nash E, Choyce J, Carrolan V, Justice E, Shaw K, Sitch A, et al.
Ther Adv Respir Dis
. 2022 Mar;
16:17534666211070133.
PMID: 35274585
Background: Home monitoring (HM) is able to detect more pulmonary exacerbations (PEx) than routine care (RC) in individuals with cystic fibrosis (CF), but there is currently no evidence for benefits...
2.
Kempegowda P, Sunsoa H, Chandan J, Quinn L, Amrelia P, Atta S, et al.
Ther Adv Endocrinol Metab
. 2022 Feb;
11:2042018820966428.
PMID: 35154634
Aims: To study the prevalence of microvascular complications and renal changes associated with cystic fibrosis-related diabetes (CFRD). Methods: This retrospective cohort study was conducted at the West Midlands Adult Cystic...
3.
Webb K, Zain N, Stewart I, Fogarty A, Nash E, Whitehouse J, et al.
J Med Microbiol
. 2022 Feb;
71(2).
PMID: 35113780
Although anaerobic bacteria exist in abundance in cystic fibrosis (CF) airways, their role in disease progression is poorly understood. We hypothesized that the presence and relative abundance of the most...
4.
Barrett J, Slatter G, Whitehouse J, Nash E
J Hum Nutr Diet
. 2021 Dec;
35(5):757-764.
PMID: 34914145
Background: Cystic fibrosis (CF) is a multisystem disorder that primarily affects the respiratory and gastrointestinal systems. Dietetic therapy is a prominent aspect of CF management, with patients receiving nutritional surveillance...
5.
Zain N, Webb K, Stewart I, Halliday N, Barrett D, Nash E, et al.
J Med Microbiol
. 2021 Oct;
70(10).
PMID: 34596013
produces quorum sensing signalling molecules including 2-alkyl-4-quinolones (AQs), which regulate virulence factor production in the cystic fibrosis (CF) airways. Culture can lead to condition-dependent artefacts which may limit the potential...
6.
Webb K, Camara M, Zain N, Halliday N, Bruce K, Nash E, et al.
J Cyst Fibros
. 2021 Sep;
21(4):626-629.
PMID: 34518117
Pseudomonas aeruginosa produces specific signalling molecules, 2-alkyl-4-quinolones (AQs) that are detectable in the sputum of adults with cystic fibrosis (CF) and who have pulmonary infection with this opportunistic pathogen. This...
7.
Taylor-Cousar J, Jain R, Kazmerski T, Aitken M, West N, Wilson A, et al.
J Cyst Fibros
. 2020 Aug;
20(3):395-396.
PMID: 32800485
Chronic oral azithromycin therapy improves clinical outcomes in people with cystic fibrosis (CF), and is recommended for treatment of CF lung disease. Azithromycin is categorized as pregnancy class B. The...
8.
Nash E, Middleton P, Taylor-Cousar J
J Cyst Fibros
. 2020 Mar;
19(4):521-526.
PMID: 32151568
Background: As their long-term prognosis improves, women with CF are increasingly choosing to have children, but the safety of CFTR modulators in pregnancy and breastfeeding is currently unknown. Methods: A...
9.
Keyte R, Egan H, Nash E, Regan A, Jackson C, Mantzios M
Psychol Health Med
. 2019 Dec;
25(8):1013-1019.
PMID: 31870175
Health risk behaviours (HRBs) are prevalent within the cystic fibrosis (CF) population, and there is a lack of research around what influences their engagement. This research explored beliefs associated with...
10.
Palser S, Smith S, Nash E, Agarwal A, Smyth A
Cochrane Database Syst Rev
. 2019 Dec;
12:CD012300.
PMID: 31845758
Background: Chronic infection with Pseudomonas aeruginosa (PA) in cystic fibrosis (CF) is a source of much morbidity and mortality. Eradication of early PA infection is possible, but can recur in...